{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:28Z","timestamp":1791385228754,"version":"4.3.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01054-3","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:31:05Z","timestamp":1791383465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on the Use of a Bayesian Approach in Designing Seamless Phase 2\/3 Clinical Trials with Dose Selection, Early Stopping for Futility and Efficacy, or Sample Size Re-estimation"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5167-904X","authenticated-orcid":false,"given":"Natalia","family":"Muehlemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Priel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vandemeulebroecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ohlssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Ionan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1054_CR1","unstructured":"IQVIA Institute. Global Trends in R&D 2024: Activity, Productivity, and Enablers. February; 2024."},{"issue":"3","key":"1054_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/10543406.2014.888569","volume":"24","author":"KR Broglio","year":"2014","unstructured":"Broglio KR, Connor JT, Berry SM. Not too big, not too small: a goldilocks approach to sample size selection. J Biopharm Stat. 2014;24(3):685\u2013705. https:\/\/doi.org\/10.1080\/10543406.2014.888569.","journal-title":"J Biopharm Stat"},{"key":"1054_CR3","doi-asserted-by":"publisher","unstructured":"Ryan EG, Bruce J, Metcalfe AJ et al. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. BMC Med Res Methodol. 2019;19(1):99. https:\/\/doi.org\/10.1186\/s12874-019-0739-3.","DOI":"10.1186\/s12874-019-0739-3"},{"issue":"1","key":"1054_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13063-019-4024-x","volume":"21","author":"EG Ryan","year":"2020","unstructured":"Ryan EG, Stallard N, Lall R, et al. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial. Trials. 2020;21(1):84. https:\/\/doi.org\/10.1186\/s13063-019-4024-x.","journal-title":"Trials"},{"key":"1054_CR5","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1007\/s43441-025-00861-4","volume":"59","author":"R Mukherjee","year":"2025","unstructured":"Mukherjee R, Muehlemann N, Gao Y, et al. Adaptive design with Bayesian informed interim decisions: application to a randomized trial of mechanical circulatory support. Therapeutic Innov Regul Sci. 2025;59:1516\u201325. https:\/\/doi.org\/10.1007\/s43441-025-00861-4.","journal-title":"Therapeutic Innov Regul Sci"},{"issue":"4","key":"1054_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1740774514531352","volume":"11","author":"BR Saville","year":"2014","unstructured":"Saville BR, Connor JT, Ayers GD, et al. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials. 2014;11(4):485\u201393. https:\/\/doi.org\/10.1177\/1740774514531352.","journal-title":"Clin Trials"},{"issue":"2","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","volume":"77","author":"AM Wessels","year":"2020","unstructured":"Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials. JAMA Neurol. 2020;77(2):199\u2013209. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3988.","journal-title":"JAMA Neurol"},{"key":"1054_CR8","doi-asserted-by":"publisher","unstructured":"Bretz F, Schmidli H, K\u00f6nig F et al. Confirmatory seamless Phase II\/III clinical trials with hypothesis selection at interim: general concepts. Biom J. 48:623\u201334. https:\/\/doi.org\/10.1002\/bimj.200510232.","DOI":"10.1002\/bimj.200510232"},{"key":"1054_CR9","doi-asserted-by":"publisher","unstructured":"Brannath W, K\u00f6nig F, Bauer P. Multiplicity and flexibility in clinical trials. Pharm Stat. 2007;6(3):205\u201316. https:\/\/doi.org\/10.1002\/pst.302.","DOI":"10.1002\/pst.302"},{"issue":"6","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/10543400701645215","volume":"17","author":"C Jennison","year":"2007","unstructured":"Jennison C, Turnbull BW. Adaptive seamless designs: selection and prospective testing of hypotheses. J Biopharm Stat. 2007;17(6):1135\u201361. https:\/\/doi.org\/10.1080\/10543400701645215.","journal-title":"J Biopharm Stat"},{"issue":"4","key":"1054_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.12793\/tcp.2023.31.e21","volume":"31","author":"H Lee","year":"2023","unstructured":"Lee H, Hwang S, Jang I-J, et al. Adaptive design clinical trials: current status by disease and trial phase in various perspectives. Transl Clin Pharmacol. 2023;31(4):202\u201316. https:\/\/doi.org\/10.12793\/tcp.2023.31.e21.","journal-title":"Transl Clin Pharmacol"},{"key":"1054_CR12","doi-asserted-by":"publisher","unstructured":"Cuffe S, Lawrence D, Stone A, et al. When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharm Stat. 2014;13(4):229\u201337. https:\/\/doi.org\/10.1002\/pst.1622.","DOI":"10.1002\/pst.1622"},{"key":"1054_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/216847900604000412","volume":"40","author":"J Maca","year":"2006","unstructured":"Maca J, Bhattacharya S, Dragalin V, et al. Adaptive Seamless Phase II\/III Designs \u2013 Background, Operational Aspects, and Examples. Ther Innov Regul Sci. 2006;40:463\u201373. https:\/\/doi.org\/10.1177\/216847900604000412.","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"1054_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s43441-022-00483-0","volume":"57","author":"AC Ionan","year":"2023","unstructured":"Ionan AC, Clark J, Travis J, et al. Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER. Ther Innov Regul Sci. 2023;57(3):436\u201344. https:\/\/doi.org\/10.1007\/s43441-022-00483-0.","journal-title":"Ther Innov Regul Sci"},{"key":"1054_CR15","doi-asserted-by":"crossref","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Wiley; 2004.","DOI":"10.1002\/0470092602"},{"issue":"3","key":"1054_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s43441-021-00357-x","volume":"57","author":"J Clark","year":"2022","unstructured":"Clark J, Muhlemann N, Natanegara F, et al. Why are not there more Bayesian clinical trials? Perceived barriers and educational preferences among medical researchers involved in drug development. Ther Innov Regul Sci. 2022;57(3):417\u201325. https:\/\/doi.org\/10.1007\/s43441-021-00357-x.","journal-title":"Ther Innov Regul Sci"},{"key":"1054_CR17","unstructured":"FDA, Guidance for Industry. Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products. January 2026. Available at: Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products | FDA."},{"issue":"3","key":"1054_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","volume":"22","author":"SJ Ruberg","year":"2023","unstructured":"Ruberg SJ, Beckers F, Hemmings R, et al. Application of Bayesian approaches in drug development: starting a virtuous cycle. Nat Rev Drug Discov. 2023;22(3):235\u201350. https:\/\/doi.org\/10.1038\/s41573-023-00638-0.","journal-title":"Nat Rev Drug Discov"},{"key":"1054_CR19","doi-asserted-by":"publisher","unstructured":"Kunzmann K, Grayling MJ, Lee KM et al. A Review of bayesian perspectives on sample size derivation for confirmatory trials. Am Stat. 75(4):424\u201332. https:\/\/doi.org\/10.1080\/00031305.2021.1901782.","DOI":"10.1080\/00031305.2021.1901782"},{"key":"1054_CR20","unstructured":"FDA. Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry: Guidance for Industry. November 2019. Available at: https:\/\/www.fda.gov\/media\/78495\/download."},{"key":"1054_CR21","doi-asserted-by":"publisher","unstructured":"Mayer C, Perevozskaya I, Leonov S et al. Simulation practices for adaptive trial designs in drug and device development. Stat Biopharm Res. 11(4):325\u201335. https:\/\/doi.org\/10.1080\/19466315.2018.1560359.","DOI":"10.1080\/19466315.2018.1560359"},{"key":"1054_CR22","unstructured":"FDA. Demonstrating substantial evidence of effectiveness for human drug and biological products: Guidance for industry (Draft guidance, Revision 1). 2026. Available at: https:\/\/www.fda.gov\/media\/133660\/download"},{"key":"1054_CR23","unstructured":"FDA. Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases: guidance for industry. 2024. Available at: https:\/\/www.fda.gov\/media\/164555\/download."},{"key":"1054_CR24","unstructured":"FDA. Project Optimus. Available at: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus. Assessed April 2026."},{"issue":"18","key":"1054_CR25","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1158\/1078-0432.CCR-11-3118","volume":"18","author":"JJ Zhang","year":"2012","unstructured":"Zhang JJ, Blumenthal GM, He K, et al. Overestimation of the effect size in group sequential trials. Clin Cancer Res. 2012;18(18):4872\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3118.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1054_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s43441-019-00002-8","volume":"54","author":"E Bloomquist","year":"2020","unstructured":"Bloomquist E, Jin S, Zhou J, Et. An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer. Ther Innov Regul Sci. 2020;54(4):861\u20139. https:\/\/doi.org\/10.1007\/s43441-019-00002-8.","journal-title":"Ther Innov Regul Sci"},{"issue":"6","key":"1054_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/1740774516649595","volume":"13","author":"H Wang","year":"2016","unstructured":"Wang H, Rosner GL, Goodman SN. Quantifying over-estimation in early stopped clinical trials and the freezing effect on subsequent research. Clin Trials. 2016;13(6):621\u201331. https:\/\/doi.org\/10.1177\/1740774516649595.","journal-title":"Clin Trials"},{"issue":"2","key":"1054_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1740774509102310","volume":"6","author":"B Freidlin","year":"2009","unstructured":"Freidlin B, Korn EL. Stopping clinical trials early for benefit: impact on estimation. Clin Trials. 2009;6(2):119\u201325. https:\/\/doi.org\/10.1177\/1740774509102310.","journal-title":"Clin Trials"},{"issue":"24","key":"1054_CR29","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1002\/sim.2389","volume":"24","author":"M Posch","year":"2005","unstructured":"Posch M, Koenig F, Branson M, et al. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med. 2005;24(24):3697\u2013714. https:\/\/doi.org\/10.1002\/sim.2389.","journal-title":"Stat Med"},{"key":"1054_CR30","unstructured":"Holzhauer B, Weber S. Applied Modelling in Drug Development. 15 - Bayesian mixed effects model for repeated measures. Novartis AG; 2025, https:\/\/opensource.nibr.com\/bamdd\/src\/02h_mmrm.html."},{"key":"1054_CR31","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Rubio V. Bayesian Inference with INLA. Chapman & Hall\/CRC; 2020. https:\/\/doi.org\/10.1201\/9781315175584.","DOI":"10.1201\/9781315175584"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01054-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01054-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01054-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:31:07Z","timestamp":1791383467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-01054-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":31,"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01054-3","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}